Clinical trial
SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
NCT00169520 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00169520 |
|---|---|
| Title | SB-715992 In Combination With Docetaxel In Patients With Solid Tumors |
| Official title | A Phase I, Open-Label Study of SB-715992 in Combination With Docetaxel in Patients With Advanced Solid Tumors. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, SB-715992 |
| Enrollment | 30 |
| Start date | Jun 1, 2004 |
| First posted | Sep 15, 2005 |
| Last update posted | Oct 16, 2008 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: